Study of an antiangiogenesis gene therapy with endostatin on endometriosis in the nude mouse model

Ma Y, Y Ma, He YL, Y L He

Clinical and experimental obstetrics & gynecology · 2014 · doi:10.12891/ceog17172014 · PMID:24992787

other OA: bronze public-domain-us

🔓 Open OA copy Full text JSON View on PubMed View at publisher

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-09 ⓘ

Recombinant adenovirus carrying endostatin induced apoptosis and inhibited endometriotic lesion growth and microvessel density in a nude mouse model.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-09 · read from full text ⓘ

This study evaluated an antiangiogenesis gene therapy using endostatin delivered by a recombinant adenovirus (Ad-ES) in a nude mouse model of endometriosis. The authors constructed Ad-ES, assessed apoptosis induction in ECV-304 cells, then established subcutaneous endometriosis lesions by implantation and injected the local foci with Ad-ES, Ad-Track, or physiologic saline, measuring lesion morphology, lesion volume, microvessel density (MVD), and apoptosis. Ad-ES successfully induced apoptosis in ECV-304 cells and, in mice, was associated with significantly smaller endometriotic lesion volumes and reduced MVD compared with the two control groups, alongside increased cellular apoptosis. The paper’s limitation is that the in vivo work relies on a nude mouse xenograft model and does not detail translation-relevant endpoints beyond morphological, vascular, and apoptosis measures. This paper is centrally about endometriosis — it tests endostatin gene therapy’s effects on lesion growth, microvessel density, and apoptosis in a nude mouse endometriosis model.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

AIM: This work aims to investigate the treatment effect of endostatin (ES) in the nude mouse model with endometriosis (EMs). MATERIALS AND METHODS: Recombinant adenovirus Ad-ES carrying ES gene was constructed. Apoptosis of ECV-304 cell induced by Ad-ES was observed. The nude mouse model with EMs was established by subcutaneous implantation. After the local focus was injected with the Ad-ES, the Ad-Track or the physiologic saline, respectively, the morphological features of ectopic focuses were observed under microscopy. The microvessel densities (MVD) and the apoptosis were detected. RESULTS: The recombinant Ad-ES was successfully constructed. Apoptosis of ECV 304 cells could be induced by Ad-ES. The nude mouse model with EMs was successfully established by subcutaneous implantation. There were statistical differences in the volumes of endometriotic lesions and MVD after treatment by Ad-ES compared with those in the other two control groups (p < 0.05). Apoptosis of the cells were significantly increased in the group of treatment by Ad-ES compared with those of the two control groups. CONCLUSION: ES could induce ECV 304 cells to apoptosis and inhibit the growth ofendometrium in the nude mouse model. The findings suggest that antiangiopoiesis may be used as a promising therapy for the treatment of EMs.

Full text 1,938 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Aim: This work aims to investigate the treatment effect of endostatin (ES) in the nude mouse model with endometriosis (EMs). Materials and Methods: Recombinant adenovirus Ad-ES carrying ES gene was constructed. Apoptosis of ECV-304 cell induced by Ad-ES was observed. The nude mouse model with EMs was established by subcutaneous implantation. After the local focus was injected with the Ad-ES, the Ad-Track or the physiologic saline, respectively, the morphological features of ectopic focuses were observed under microscopy. The microvessel densities (MVD) and the apoptosis were detected. Results: The recombinant Ad-ES was successfully constructed. Apoptosis of ECV 304 cells could be induced by Ad-ES. The nude mouse model with EMs was successfully established by subcutaneous implantation. There were statistical differences in the volumes of endometriotic lesions and MVD after treatment by Ad- ES compared with those in the other two control groups (p < 0.05). Apoptosis of the cells were significantly increased in the group of treatment by Ad-ES compared with those of the two control groups. Conclusion: ES could induce ECV 304 cells to apoptosis and inhibit the growth of endometrium in the nude mouse model. The findings suggest that antiangiopoiesis may be used as a promising therapy for the treatment of EMs.

Keywords

- Endostatin - Endometriosis - Antiangiogenesis - Nude mouse - Apoptosis

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Disease Models, Animal Endometriosis Endostatins Genetic Therapy Neovascularization, Pathologic Adenoviridae Adult Animals Apoptosis Apoptosis Endometriosis Endometriosis Endostatins Female Genetic Therapy Genetic Vectors Humans Mice Mice, Inbred BALB C Mice, Nude

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc: last seen: 2026-08-30T09:23:35.175841+00:00
pubmed: last seen: 2026-05-13T22:18:22.440000+00:00
unpaywall: last seen: 2026-05-16T02:00:00.672124+00:00

License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine